Literature DB >> 9634558

Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons.

B A Horger1, M C Nishimura, M P Armanini, L C Wang, K T Poulsen, C Rosenblad, D Kirik, B Moffat, L Simmons, E Johnson, J Milbrandt, A Rosenthal, A Bjorklund, R A Vandlen, M A Hynes, H S Phillips.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) exhibits potent effects on survival and function of midbrain dopaminergic (DA) neurons in a variety of models. Although other growth factors expressed in the vicinity of developing DA neurons have been reported to support survival of DA neurons in vitro, to date none of these factors duplicate the potent and selective actions of GDNF in vivo. We report here that neurturin (NTN), a homolog of GDNF, is expressed in the nigrostriatal system, and that NTN exerts potent effects on survival and function of midbrain DA neurons. Our findings indicate that NTN mRNA is sequentially expressed in the ventral midbrain and striatum during development and that NTN exhibits survival-promoting actions on both developing and mature DA neurons. In vitro, NTN supports survival of embryonic DA neurons, and in vivo, direct injection of NTN into the substantia nigra protects mature DA neurons from cell death induced by 6-OHDA. Furthermore, administration of NTN into the striatum of intact adult animals induces behavioral and biochemical changes associated with functional upregulation of nigral DA neurons. The similarity in potency and efficacy of NTN and GDNF on DA neurons in several paradigms stands in contrast to the differential distribution of the receptor components GDNF Family Receptor alpha1 (GFRalpha1) and GFRalpha2 within the ventral mesencephalon. These results suggest that NTN is an endogenous trophic factor for midbrain DA neurons and point to the possibility that GDNF and NTN may exert redundant trophic influences on nigral DA neurons acting via a receptor complex that includes GFRalpha1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9634558      PMCID: PMC6792569     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  26 in total

1.  Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS.

Authors:  M Trupp; N Belluardo; H Funakoshi; C F Ibáñez
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

2.  Characterization of a multicomponent receptor for GDNF.

Authors:  J J Treanor; L Goodman; F de Sauvage; D M Stone; K T Poulsen; C D Beck; C Gray; M P Armanini; R A Pollock; F Hefti; H S Phillips; A Goddard; M W Moore; A Buj-Bello; A M Davies; N Asai; M Takahashi; R Vandlen; C E Henderson; A Rosenthal
Journal:  Nature       Date:  1996-07-04       Impact factor: 49.962

3.  Renal and neuronal abnormalities in mice lacking GDNF.

Authors:  M W Moore; R D Klein; I Fariñas; H Sauer; M Armanini; H Phillips; L F Reichardt; A M Ryan; K Carver-Moore; A Rosenthal
Journal:  Nature       Date:  1996-07-04       Impact factor: 49.962

4.  Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins.

Authors:  M Sanicola; C Hession; D Worley; P Carmillo; C Ehrenfels; L Walus; S Robinson; G Jaworski; H Wei; R Tizard; A Whitty; R B Pepinsky; R L Cate
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase.

Authors:  A Buj-Bello; J Adu; L G Piñón; A Horton; J Thompson; A Rosenthal; M Chinchetru; V L Buchman; A M Davies
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

6.  A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor.

Authors:  R D Klein; D Sherman; W H Ho; D Stone; G L Bennett; B Moffat; R Vandlen; L Simmons; Q Gu; J A Hongo; B Devaux; K Poulsen; M Armanini; C Nozaki; N Asai; A Goddard; H Phillips; C E Henderson; M Takahashi; A Rosenthal
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

7.  Selective increase in dopamine utilization in the shell subdivision of the nucleus accumbens by the benzodiazepine inverse agonist FG 7142.

Authors:  B A Horger; J D Elsworth; R H Roth
Journal:  J Neurochem       Date:  1995-08       Impact factor: 5.372

8.  GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF.

Authors:  S Jing; D Wen; Y Yu; P L Holst; Y Luo; M Fang; R Tamir; L Antonio; Z Hu; R Cupples; J C Louis; S Hu; B W Altrock; G M Fox
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

9.  Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons.

Authors:  K E Bowenkamp; A F Hoffman; G A Gerhardt; M A Henry; P T Biddle; B J Hoffer; A C Granholm
Journal:  J Comp Neurol       Date:  1995-05-15       Impact factor: 3.215

10.  Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts.

Authors:  P L Durbec; L B Larsson-Blomberg; A Schuchardt; F Costantini; V Pachnis
Journal:  Development       Date:  1996-01       Impact factor: 6.868

View more
  72 in total

1.  Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

Authors:  Kc Biju; Qing Zhou; Guiming Li; Syed Z Imam; James L Roberts; William W Morgan; Robert A Clark; Senlin Li
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

2.  Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.

Authors:  Wayne A Cass; Laura E Peters
Journal:  Neurochem Int       Date:  2010-07-06       Impact factor: 3.921

3.  Anatomical basis of glial cell line-derived neurotrophic factor expression in the striatum and related basal ganglia during postnatal development of the rat.

Authors:  Tinmarla Frances Oo; Vincent Ries; Jinwhan Cho; Nikolai Kholodilov; Robert E Burke
Journal:  J Comp Neurol       Date:  2005-03-28       Impact factor: 3.215

Review 4.  Trophic factors therapy in Parkinson's disease.

Authors:  Shilpa Ramaswamy; Katherine E Soderstrom; Jeffrey H Kordower
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

Review 5.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

Review 6.  Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-02-07       Impact factor: 5.590

Review 7.  Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.

Authors:  Tiago Martins Rodrigues; André Jerónimo-Santos; Tiago Fleming Outeiro; Ana Maria Sebastião; Maria José Diógenes
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

8.  Receptors of the glial cell line-derived neurotrophic factor family of neurotrophic factors signal cell survival through the phosphatidylinositol 3-kinase pathway in spinal cord motoneurons.

Authors:  R M Soler; X Dolcet; M Encinas; J Egea; J R Bayascas; J X Comella
Journal:  J Neurosci       Date:  1999-11-01       Impact factor: 6.167

9.  Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Authors:  X Yue; D J Hariri; B Caballero; S Zhang; M J Bartlett; O Kaut; D W Mount; U Wüllner; S J Sherman; T Falk
Journal:  Neuroscience       Date:  2013-11-27       Impact factor: 3.590

10.  Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.

Authors:  Fredric P Manfredsson; Nihal Tumer; Benedek Erdos; Tessa Landa; Christopher S Broxson; Layla F Sullivan; Aaron C Rising; Kevin D Foust; Yi Zhang; Nicholas Muzyczka; Oleg S Gorbatyuk; Philip J Scarpace; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.